Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 48.90

-0.8%

10:38 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (23349)	3/29/2007 2:45:06 PM
From: scaram(o)uche	Read Replies (1) of 52153

>> but DNDN rep just explicitly said that indeed the only 'proof' they have of potency is the 4 month added survival << Message 23412661 always had a manufacturability concern >> candidate for adaptive designed trials << Sounds good to me, in a public company context. Patient-specific stuff mostly doesn't overlap that context. It would also be good to make it work, given a system where $gazzillions can be wrapped up in ever-lasting B.S.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next